There are 2934 resources available
6572 - CheckMate 459: A Randomized, Multi-Center Phase 3 Study of Nivolumab (NIVO) vs Sorafenib (SOR) as First-Line (1L) Treatment in Patients (pts) With Advanced Hepatocellular Carcinoma (aHCC)
Presenter: Thomas Yau
Session: Proffered Paper 1 – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
5130 - OCTOPUS - A Randomised, Multi-centre Phase II Umbrella Trial of Weekly Paclitaxel+/- Novel Agents in Platinum-Resistant Ovarian Cancer: vistusertib
Presenter: Susana Banerjee
Session: Proffered Paper 1 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Proffered Paper 1 - NSCLC, metastatic - Invited Discussant 1478O and 1479O
Presenter: Lizza Hendriks
Session: Proffered Paper 1 - NSCLC, metastatic
Resources:
Slides
Webcast
Proffered Paper 1 - NSCLC, metastatic - Invited Discussant LBA79 and LBA80
Presenter: Naiyer Rizvi
Session: Proffered Paper 1 - NSCLC, metastatic
Resources:
Slides
Webcast
Systemic treatment
Presenter: Giovanni Grignani
Session: ESMO-ESOI Collaborative session: Gastrointestinal stromal tumours: Imaging and treatment
Resources:
Slides
Webcast
Outcome of the 2019 United Nation’s high-level meeting on universal health coverage
Presenter: André Ilbawi
Session: Universal health coverage and cancer: What you and your country need to know
Resources:
Slides
Webcast
The methodology and country support for setting cancer priorities for universal health coverage
Presenter: Dario Trapani
Session: Universal health coverage and cancer: What you and your country need to know
Resources:
Slides
Webcast
Including cancer services in universal health coverage packages
Presenter: André Ilbawi
Session: Universal health coverage and cancer: What you and your country need to know
Resources:
Slides
Webcast
2560 - BAROCCO: A randomized phase II study of weekly paclitaxel vs. cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC)
Presenter: Nicoletta Colombo
Session: Proffered Paper 1 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast
6602 - Phase 1B/2 Study of AVB500 (High Affinity Inhibitor of GAS6/AXL Path) in Combination with PAC and PLD in Platinum Resistant Recurrent Ovarian Cancer
Presenter: Bradley Monk
Session: Proffered Paper 1 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast